AdAlta expands partnership with Alfred Hospital
Released
Released
Announcement PDF
ASX Announcement
AdAlta expands partnership with world-leading fibrosis research
team at Melbourne’s The Alfred Hospital
MELBOURNE Australia, 21 March, 2017: AdAlta Limited (ASX: 1AD), the biotechnology
company advancing its lead i-body candidate towards clinical development today
announced the continuation of its collaboration with The Alfred hospital in Melbourne,
Australia, and the clinical research team led by Dr Glen Westall, an expert in lung fibrosis
and Idiopathic Pulmonary Fibrosis (IPF).
Fibrosis accounts for 45 per cent of all diseases globally in the developed world and
represents a large unmet medical need.
The expanded collaboration between AdAlta and The Alfred to further validate AD-114’s
role in the treatment of IPF will run for an additional six months and will be funded by an
Innovation Connection grant from the Australian Federal Government as well as AdAlta’s
research and development, and clinical budget.
AdAlta Chief Executive Officer Sam Cobb said “Our multiple collaborations and strategic
alliances across commercial, clinical and manufacturing areas with world-leading partners,
such as the team at The Alfred, further enhance the potential for the success of our new
treatments for fibrosis.”
Respiratory Physician at The Alfred hospital, Dr Glen Westall and his team are
international leaders in the field of lung fibrosis with access to human IPF patient
tissue for evaluation with AdAlta’s lead candidate AD-114.
Dr Westall, said, “We are excited to continue working with AdAlta to further
understand this complex fibrotic disease and how the Company’s novel i-body may
play a role in the treatment of IPF, for which there is currently no cure.”
Dr Westall recently spoke at AdAlta’s inaugural fibrosis investor briefing, where he
provided an overview of IPF and currently available treatments. The full-length
presentation is available on AdAlta’s website as well as a video highlight of the day.
-ENDSNotes to Editors
About AdAlta
AdAlta Limited is an Australian based drug development company headquartered in
Melbourne. The Company is focused on using its proprietary technology platform to
generate i-bodies, a new class of protein therapeutics, with applications as
therapeutic drugs to treat disease.
The i-body is a human analogue of the antigen binding domain of the shark antibody,
which combines the advantages of monoclonal antibodies (high target specificity and
affinity) with the beneficial stability features of small molecules. In addition to stability,
the i-body has a long binding loop that is a feature of shark antibodies not present in
either human or next generation antibodies. This feature enables the i-body to
recognise and bind to a diverse range of different therapeutically-relevant drug
targets, including those that are difficult/intractable to access by current antibody
therapies. These include clinically important targets such as G-protein coupled
receptors (GPCRs) and ion channels.
AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic
pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current
therapies are sub-optimal and there is a high-unmet medical need.
The Company also plans to continue further drug discovery and development
directed towards other drug targets and diseases with its i-body technology platform.
Further information can be found at: www.adalta.com.au.
For more information, please contact:
AdAlta Limited
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159
E: s.cobb@adalta.com.au
Media (Australia)
Andrew Geddes
Tel: +61 (0)408 677 734
E: adalta@instinctif.com
Media (International)
Sue Charles / Daniel Gooch
Tel: +44 (0)20 7866 7905
E: adalta@instinctif.com
Share your feedback
Discover